| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.0031 | 1 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.0021 | 1 |